2025-11-05T13:35:03-06:00 2024-12-31 331374517 PKF O'CONNOR DAVIES ADVISORY LLC 500 MAMARONECK AVENUE SUITE 301 HARRISON NY 105281633 990 2024-01-01 133806788 THE OVARIAN CANCER RESEARCH FUND INC OVAR 2122681002 45 ROCKEFELLER PLAZA 20TH FLOOR NEW YORK NY 101113193 AUDRA L MORAN PRESIDENT & CEO 2122681002 2025-11-05 1 1 MELISSA MODELSON P01603524 9143818900 2025-11-05 2024 2025-03-06 01:10:19Z OVARIAN CANCER RESEARCH ALLIANCE AUDRA L MORAN 45 ROCKEFELLER PLAZA 20TH FLOOR NEW YORK NY 101113193 21854917 0 X WWW.OCRAHOPE.ORG X 1994 NY OVARIAN CANCER RESEARCH ALLIANCE IS COMMITTED TO PREVENTING, DEVELOPING BETTER TREATMENTS FOR AND ULTIMATELY CURING OVARIAN AND RELATED GYNECOLOGIC CANCERS THROUGH INNOVATIVE RESEARCH, RAISING AWARENESS AND ENSURING THE BEST CARE POSSIBLE THROUGH ADVOCACY AND SUPPORT FOR PATIENTS AND FAMILIES. 19 19 21 1869 0 0 11556311 8538194 438937 301023 1447267 1219860 0 -11079 13442515 10047998 8117910 6428064 0 0 3064716 2887953 0 0 1425591 2570134 4240499 13752760 13556516 -310245 -3508518 39203357 38070603 14720293 14914782 24483064 23155821 X OVARIAN CANCER RESEARCH ALLIANCE (OCRA) IS COMMITTED TO PREVENTING, DEVELOPING BETTER TREATMENTS FOR AND ULTIMATELY CURING OVARIAN AND RELATED GYNECOLOGIC CANCERS THROUGH INNOVATIVE RESEARCH, RAISING AWARENESS AND ENSURING THE BEST CARE POSSIBLE THROUGH ADVOCACY AND SUPPORT FOR PATIENTS AND FAMILIES. 0 0 7227647 6318064 0 OVARIAN CANCER RESEARCH ALLIANCE WAS FOUNDED IN 1994 (AS THE OVARIAN CANCER RESEARCH FUND, INC.) AND IS A FULL-SPECTRUM ORGANIZATION FUNDING MEDICAL RESEARCH, ADVOCATING ON BEHALF OF PATIENTS AND PROVIDING SUPPORT AND RESOURCES TO PATIENTS AND THEIR FAMILIES.OVARIAN CANCER IS THE DEADLIEST OF ALL GYNECOLOGIC CANCERS AND RANKS FIFTH AS THE CAUSE OF CANCER DEATH IN WOMEN. IN 2024, THERE WERE 19,680 NEW CASES OF OVARIAN CANCER AND 12,740 DEATHS FROM THE DISEASE IN THE UNITED STATES. THE ACCOMPLISHMENTS OF OCRA'S PROGRAMS REFLECT OUR COMMITMENT TO THE OVARIAN AND GYNECOLOGIC CANCER COMMUNITIES. SINCE 1998, OCRA HAS AWARDED 435 GRANTS FOR OVARIAN AND RELATED CANCER RESEARCH TO PHYSICIANS AND SCIENTISTS AT 99 LEADING MEDICAL CENTERS, WHICH IS AN INVESTMENT TOTALING OVER $129 MILLION. THANKS TO THE GENEROSITY OF OUR DONORS, OUR INVESTIGATORS ARE WORKING ON MANY FRONTS TO DEFEAT OVARIAN CANCER. BY DEVELOPING INNOVATIVE STRATEGIES FOR EARLY DETECTION AND EXPLORING THE GENETICS THAT INCREASE RISK FOR OVARIAN CANCER, WE HOPE TO SAVE WOMEN'S LIVES BY FINDING THE CANCER EARLY OR STOPPING IT BEFORE IT EVEN STARTS. RESEARCHERS ARE GAINING INSIGHTS INTO THE MANY TYPES OF OVARIAN AND RELATED CANCERS TO DETERMINE THE ORIGINS, WHICH MAY LEAD TO MORE EFFECTIVE TESTING AND EFFECTIVE IMMUNOTHERAPY TREATMENT OPTIONS. FURTHERMORE, THEY ARE IDENTIFYING NEW AND BETTER TREATMENTS TO IMPROVE OVERALL SURVIVAL, PREVENT DRUG RESISTANCE, MINIMIZE SIDE EFFECTS, PREVENTING RECURRENCE AND METASTASIS, AND ENHANCE PATIENTS' QUALITY OF LIFE. OCRA CONTINUED THE HEALTH EQUITY RESEARCH GRANTS BEGUN IN 2023. THESE GRANTS FOCUS ON IMPROVING HEALTH EQUITY IN THE GYNECOLOGIC CANCER SPACE.ACCOMPLISHMENTS ACHIEVED AS A RESULT OF OCRA GRANTS INCLUDE:IDENTIFIED A MOLECULE THAT COULD BE KEY TO IMPROVING IMMUNE RESPONSE AGAINST OVARIAN CANCER; HIGHLIGHTED THE NEED FOR INDIVIDUAL ASSESSMENT OF COMPLEX VARIANTS TO CORRECTLY IDENTIFY INDIVIDUALS AT RISK; SOUGHT TO UNDERSTAND WHY CERTAIN OVARIAN CANCER CELLS RESIST OLAPARIB TREATMENT, AND DISCOVERED THAT INTRODUCING A SECOND DRUG (MIFEPRISTONE) WHILE TARGETING CERTAIN CELLS (POLYPLOID GIANT CANCER CELLS) MAY OFFER A SOLUTION; IDENTIFIED A PREVIOUSLY UNKNOWN CHEMORESISTANT PATHWAY IN HGSC WHICH LED TO WORKING ON A NEW THERAPY TO OVERCOME THIS; FOUND THAT MESOTHELIAL CELLS ARE IMPORTANT TO THE INITIAL STAGES OF OVARIAN CANCER GROWTH IN THE ABDOMINAL CAVITY; SHED NEW LIGHT ON HOW THE MOST COMMON SUBTYPE OF OVARIAN CANCER DEVELOPS AND METASTASIZES, BY IDENTIFYING A KEY MOLECULE THAT ALLOWS MALIGNANCIES IN THE FALLOPIAN TUBE TO MIGRATE TO THE OVARIES AND CONTINUE TO GROW; UNCOVERED SEVERAL MECHANISMS OF IMMUNE ESCAPE TO HELP EXPLAIN SOME OVARIAN CANCERS' RESISTANCE TO IMMUNOTHERAPY; SHOWN THAT RUCAPARIB EXTENDS PROGRESSION FREE SURVIVAL IN OVARIAN CANCER; DISCOVERED THAT 18% OF OVARIAN CANCER CASES INVOLVE INHERITED MUTATIONS; PINPOINTED TWO GENES THAT TRIGGER OVARIAN CANCER; IDENTIFIED A NEW THERAPEUTIC STRATEGY FOR CLEAR CELL OVARIAN CANCER; SHOWN HOW A PARP/IMMUNE THERAPY COMBO SHOWS PROMISE; DEMONSTRATED HOW GENE THERAPY MAY HELP PATIENTS WITH RECURRENT DISEASE; SHED LIGHT ON HOW OVARIAN CANCER GROWS; DISCOVERED THAT ANALYZING DATA FROM PAP SMEARS COULD HELP DETECT ENDOMETRIAL AND OVARIAN CANCER; ESTABLISHED THERE IS NO LINK BETWEEN OBESITY AND RISK FOR THE MOST COMMON TYPE OF OVARIAN CANCER; SHOWN THAT FGFR4 IS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET FOR OVARIAN CANCER; DEFINED SIMILARITIES BETWEEN SOME ENDOMETRIAL, BREAST AND OVARIAN CANCERS; EXPLAINED HOW AN EXPERIMENTAL DRUG MAY BE HELPFUL IN FIGHTING PLATINUM-RESISTANT OVARIAN CANCER; IDENTIFIED AREAS OF THE HUMAN GENOME THAT ARE LINKED TO INCREASED RISK FOR OVARIAN CANCER; IDENTIFIED BIOMARKERS THAT CAN BE USED TO MONITOR THE DEVELOPMENT OF PLATINUM RESISTANCE THERAPIES; STUDIED MACROPHAGES TO IMPROVE TREATMENT; IDENTIFIED NOVEL BIOMARKERS OF HGSOC AND SPECIFIC DRUG TARGETS; TARGETED MDM2 DEGRADATION AS A NOVEL TREATMENT FOR OVARIAN CANCER; USED MACHINE LEARNING TO BRIDGE THE GAP BETWEEN DISPARATE DATA SETS SPECIFICALLY IN PATIENTS WITH HGSOC; DOSED THE FIRST PATIENTS IN THE CLINICAL TRIAL "IMMUNOTHERAPY PLATFORM STUDY IN PLATINUM RESISTANT HIGH GRADE SEROUS OVARIAN CANCER (IPROC)" (NCT04918186); FOUND KEY PROTEINS IN HGSOC CANCER CELLS WHICH RESULTED IN COMBINED TREATMENT OPTIONS WHICH RESULTED IN SMALLER TUMORS AND LONGER SURVIVAL; AND SHOWED HOW SURGICAL REMOVAL OF FALLOPIAN TUBES MAY REDUCE OVARIAN CANCER RISK.IN 2024 ALONE, OCRA RESEARCHERS: DEVELOPED A POSSIBLE FRAMEWORK FOR THE DEVELOPMENT OF NOVEL STRATEGIES TO IMPROVE TREATMENT OUTCOMES; SHOWED HOW RNF168 PRODUCES AND READS CHROMATIN UBIQUITYLATION; UNCOVERED SEVERAL MECHANISMS OF IMMUNE ESCAPE TO HELP EXPLAIN SOME OVARIAN CANCERS' RESISTANCE TO IMMUNOTHERAPY; FOUND A DECREASE IN OVARIAN CARCINOMA INCIDENCE AFTER SALPINGECTOMY FOR TREATING ECTOPIC PREGNANCY; SHOWED PARP1 IS INVOLVED IN REPAIR OF TELOMERES, AND THAT IMPAIRING THIS PROCESS CAN LEAD TO TELOMERE SHORTENING AND GENOMIC INSTABILITY THAT CAN CAUSE CANCER; DEVELOPED A PROOF OF CONCEPT STUDY TO SHOW HOW THREE DIMENSIONAL MODELING CAN SHOW HOW CANCER CELLS AND CAR-T INTERACT WHICH WILL HOPEFULLY LEAD TO BETTER TREATMENTS IN PATIENTS WITH HGSOC SOLID TUMORS; DISCOVERED THAT AGGRESSIVE OVARIAN CANCERS OFTEN SHOW SUDDEN LARGE-SCALE DNA DAMAGE, POINTING TO DISTINCT ORIGINS AND DETECTION STRATEGIES; CHARACTERIZED EXPRESSION OF NEARLY 500 PROTEINS FROM THOUSANDS OF CANCER SAMPLES, ENABLING INSIGHTS INTO TUMOR HETEROGENEITY, CANCER DEPENDENCIES, BIOMARKERS, AND THERAPEUTIC TARGETS; DISCOVERED THAT A PROTEIN CALLED EGFL6 HELPS OVARIAN TUMORS BLOCK THE IMMUNE SYSTEM'S ATTACK, BUT BLOCKING EGFL6 RESTORED THE EFFECTIVENESS OF IMMUNOTHERAPY IN MICE, SUGGESTING A PROMISING NEW TREATMENT TARGET; AND IDENTIFIED THAT LOSS OF A GENE CALLED SMARCA4 MAKES OVARIAN CANCER CELLS MORE VISIBLE TO THE IMMUNE SYSTEM, BOOSTING IMMUNE ATTACK AND SUGGESTING A NEW STRATEGY TO IMPROVE IMMUNOTHERAPY.EVERY DOLLAR DONATED BRINGS US CLOSER TO A CURE FOR THIS DEVASTATING DISEASE. FOR MORE INFORMATION OR TO JOIN US IN OUR FIGHT, PLEASE VISIT OCRA'S WEBSITE AT WWW.OCRAHOPE.ORG. 1708288 35000 0 BEYOND OUR CONFERENCE, OCRA HAS ADDITIONAL PATIENT EDUCATION AND SUPPORT PROGRAMS AND ENGAGES IN ADVOCACY ON BEHALF OF WOMEN WITH GYNECOLOGIC CANCERS. OUR WEBSITE IS A COMPREHENSIVE SOURCE OF EDUCATIONAL INFORMATION, AND THROUGHOUT THE COURSE OF THE YEAR WE HOLD A SERIES OF FREE, EDUCATIONAL WEBINARS ON A RANGE OF TOPICS RELATED TO THE LATEST RESEARCH, TREATMENT, AND SURVIVORSHIP.OCRA OFFERS FREE GENETIC TESTING TO QUALIFIED HIGH RISK INDIVIDUALS AND FACILITATES ACCESS TO CERTIFIED GENETIC COUNSELORS. SINCE THE LAUNCH OF THE PROGRAM, OCRA HAS HELPED OVER 3,000 PEOPLE LEARN ABOUT THEIR GENETIC RISK FOR GYNECOLOGIC CANCER. OCRA'S PATIENT-SUPPORT LINE IS STAFFED BY OUR SOCIAL WORK TEAM DURING BUSINESS HOURS MONDAY THROUGH FRIDAY AND IS AVAILABLE TO ANYONE SEEKING INFORMATION, SUPPORT, PATIENT NAVIGATION, OR RESOURCE REFERRALS (MEDICAL ADVICE IS NOT PROVIDED). OUR WOMAN TO WOMAN PROGRAM IS A PEER-TO-PEER SUPPORT PROGRAM FOR WOMEN WITH GYNECOLOGIC CANCER. OCRA OFFERS BOTH A NATIONAL WOMAN TO WOMAN PROGRAM AND PROVIDES FINANCIAL SUPPORT TO HELP HOSPITALS AND OTHER ORGANIZATIONS START LOCAL WOMAN TO WOMAN PROGRAMS, WHICH ARE NOW AT MORE THAN 19 SITES ACROSS THE COUNTRY. OUR STAYING CONNECTED SUPPORT SERIES, WHICH LAUNCHED IN 2020, NOW OFFERS FOUR WEEKLY WORKSHOPS AND THREE MONTHLY WORKSHOPS WHICH PROVIDE ALL IMPACTED BY OVARIAN OR RELATED GYNECOLOGIC CANCERS A WAY TO LEARN, SHARE, AND CONNECT. OUR ARTS PROGRAM-EXPRESS YOURSELF AND BOOK CLUB- OFFERS A COMBINATION OF THERAPEUTIC ARTS, POETRY, READING AND CREATIVE EXPRESSION, AND COMMUNITY BUILDING ACTIVITIES WITH 1865 REGISTERED IN 2024. OCRA PARTNERS WITH INSPIRE.COM TO OFFER AN ONLINE SUPPORT COMMUNITY THAT HAS OVER 85,000 MEMBERS WORLD-WIDE.OCRA IS COMMITTED TO ENCOURAGING THE NEXT GENERATION OF HEALTHCARE PROFESSIONALS TO FOCUS ON THE CRITICAL NEEDS OF THOSE DIAGNOSED WITH GYNECOLOGIC CANCER, WHETHER AT BENCH OR BEDSIDE.THROUGH OCRA'S ONCOLOGY SOCIAL WORK FIELD PLACEMENT, WE ACCEPT TOP MASTER OF SOCIAL WORK CANDIDATES TO TRAIN WITH OUR LICENSED CLINICAL SOCIAL WORKERS TO ADDRESS THE SPECIFIC NEEDS OF OUR COMMUNITY.OCRA'S SURVIVORS TEACHING STUDENTS (STS) PROGRAM TRAINS OVARIAN CANCER SURVIVORS AND CAREGIVERS TO CONDUCT PRESENTATIONS IN MEDICAL EDUCATION PROGRAMS TO EDUCATE FUTURE HEALTHCARE PROVIDERS ABOUT OVARIAN CANCER. SURVIVORS SHARE THEIR STORIES OF DIAGNOSIS, TREATMENT AND BEYOND, ALONG WITH FACTS ABOUT THE DISEASE. IN 2024, MORE THAN 980 SURVIVOR VOLUNTEERS DELIVERED 439 PRESENTATIONS IN THE US, UK, AND AUSTRALIA REACHING OVER 10,000 MEDICAL, NURSING, AND PHYSICIAN'S ASSISTANT STUDENTS. THESE PRESENTATIONS ENSURE THE NEXT GENERATION OF HEALTH CARE PROVIDERS UNDERSTAND BASIC FACTS ABOUT THE DISEASE, ARE AWARE OF RISK FACTORS, AND CAN IDENTIFY THE SIGNS AND SYMPTOMS OF OVARIAN CANCER, HELPING ENSURE A TIMELY DIAGNOSIS.OVARIAN CANCER RESEARCH ALLIANCE IS A POWERFUL VOICE ON CAPITOL HILL, IN STATEHOUSES AROUND THE COUNTRY AND WITH FEDERAL AGENCIES FOR EVERYONE TOUCHED BY GYNECOLOGIC CANCER. EACH YEAR OCRA PLAYS A CRITICAL ROLE IN HELPING TO SECURE MORE THAN $200 MILLION IN FEDERAL FUNDING FOR OVARIAN CANCER RESEARCH AND EDUCATION. IN ADDITION, OUR GROWING ADVOCATE LEADER PROGRAM TRAINS MEMBERS OF THE GYNECOLOGIC CANCER COMMUNITY TO RAISE AWARENESS THROUGH NEWS ARTICLES AND OUTREACH, DEVELOP RELATIONSHIPS WITH THEIR ELECTED OFFICIALS, AND FIGHT FOR INCREASED FUNDING FOR GYNECOLOGIC CANCER RESEARCH THROUGHOUT THE COUNTRY. 982758 75000 301023 EACH YEAR, OCRA BRINGS TOGETHER OVARIAN CANCER PATIENTS, SURVIVORS AND CAREGIVERS AT THE INTERNATIONAL GYNECOLOGIC CANCER CONFERENCE, A THREE DAY-LONG EVENT FILLED WITH INFORMATIONAL SESSIONS FEATURING EXPERT SPEAKERS, FUN AND COMMUNITY. IN 2024, MORE THAN 600 PEOPLE FROM ALL 50 STATES AND 14 COUNTRIES CAME TOGETHER VIRTUALLY FOR THIS EVENT. THE SPIRIT OF UNITY AND HOPE IS ALWAYS STRONG AND ATTENDEES CAN LEARN MORE ABOUT THEIR DIAGNOSIS, TREATMENT, AND SURVIVORSHIP. SESSIONS FEATURE TOP OVARIAN AND GYNECOLOGIC CANCER EXPERTS WHO GENEROUSLY GIVE OF THEIR TIME, PRESENTING THE LATEST IN TREATMENTS, RESEARCH, MANAGING RECURRENCE, GENETICS, NUTRITION, CARETAKER AND SUPPORTER CARE, SUPPORT FOR YOUNG WOMEN, ADVOCACY, AND SO MUCH MORE. 9918693 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 0 1 0 0 1 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 1 61 0 21 1 0 0 0 0 0 0 0 0 0 0 0 0 X 19 19 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AR CA FL GA HI IL KS KY MA MD MI MN MS ND NH NJ NM NY OR PA RI SC TN VA WI WV X X X AUDRA L MORAN 2122681002 45 ROCKEFELLER PLAZA 20TH FLOOR NEW YORK NY 101113193 JOHN ORRICO CHAIR 3.00 0.00 X X 0 0 0 MATTHEW NEAL MILLER VICE PRESIDENT 2.00 0.00 X X 0 0 0 MARK TESSAR TREASURER 2.00 0.00 X X 0 0 0 ROBIN S COHEN SECRETARY 2.00 0.10 X X 0 0 0 DEBRA BIRNBAUM DIRECTOR 1.00 0.00 X 0 0 0 THOMAS C LIEBMAN DIRECTOR 1.00 0.00 X 0 0 0 JEANNETTE CHANG DIRECTOR 1.00 0.00 X 0 0 0 DR CARMEL J COHEN DIRECTOR 1.00 0.00 X 0 0 0 MEI-LI DA SILVA VINT ESQ DIRECTOR 1.00 0.00 X 0 0 0 ANDREW FEUERSTEIN ESQ DIRECTOR 1.00 0.00 X 0 0 0 CAROL J HAMILTON DIRECTOR 1.00 0.00 X 0 0 0 JOHN W HANSBURY ESQ DIRECTOR 1.00 0.10 X 0 0 0 CAROLINE HIRSCH DIRECTOR 1.00 0.00 X 0 0 0 VERONICA JORDAN DIRECTOR 1.00 0.00 X 0 0 0 DANA L MARK ESQ DIRECTOR 1.00 0.00 X 0 0 0 CHRIS NEWCOMB DIRECTOR 1.00 0.00 X 0 0 0 LISA SCHREIBER DIRECTOR 1.00 0.00 X 0 0 0 ELLE SIMONE SCOTT DIRECTOR 1.00 0.00 X 0 0 0 CHRISTOPHER TILBERIS DIRECTOR 1.00 0.00 X 0 0 0 AUDRA L MORAN PRESIDENT & CEO 40.00 0.10 X 324287 0 33952 JONATHAN ZEIDMAN CHIEF DEVELOPMENT OFFICER 40.00 0.00 X 189019 0 53359 SARAH C DEFEO CHIEF PROGRAM OFFICER 40.00 0.00 X 166391 0 67294 TRACY MOORE VICE PRESIDENT, SUPPORT & EDUCATION 40.00 0.00 X 157837 0 27142 CHAD RAMSEY VICE PRESIDENT, POLICY 40.00 0.00 X 123276 0 25678 NICOLE WARGO VP - PHILANTHROPIC PARTNER 40.00 0.00 X 126274 0 36184 JESSICA HUGHSON ANDRADE SENIOR DIRECTOR, STRATEGIC ALLIANCE 40.00 0.00 X 108675 0 23247 BRIAN PHAIR DIRECTOR, DONOR RELATIONS 40.00 0.00 X 102012 0 5214 1297771 0 272070 8 0 1 0 ADC STRATEGIC COMMUNICATIONS 14 KNOB HL PUTNAM VALLEY NY 105793314 COMMUNICATION SERVICES 213604 BENJAMIN AUSTIN 32 MAGNOLIA DRIVE DOBBS FERRY NY 10522 MARKETING CONSULTING SERVICES 190589 AMPLIFI 600 RYERSON ROAD SUITE G LINCOLN PARK NJ 07035 MAILING SERVICES 170647 COSGROVE ACCOUNTING 11161 E STATE RD 70 STE 110-693 LAKEWOOD RANCH FL 34202 ACCOUNTING SERVICES 160524 COLOR HEALTH 831 MITTEN ROAD STE 100 BURLINGAME CA 94010 HEREDITARY TESTING KITS 110464 5 195891 8342303 684681 8538194 CONFERENCES 900099 301023 301023 301023 992906 992906 12022794 11795840 226954 226954 226954 0 195891 11079 -11079 -11079 10047998 301023 0 1208781 5673064 5673064 755000 755000 834302 648759 137600 47943 1474990 689723 165529 619738 52576 25891 5947 20738 351887 179809 45332 126746 174198 99122 22750 52326 169371 8938 160433 215632 215632 94165 94165 1070763 802454 257486 10823 251942 150547 30725 70670 727841 306672 61593 359576 201486 99368 49662 52456 174859 99489 22851 52519 53905 43613 10292 129842 129842 12375 7042 1616 3717 18852 10727 2462 5663 LEASE TERMINATION 925000 925000 GENETIC TESTING 183556 183556 OTHER OPERATING EXPENSE 5465 1973 2449 1043 MOVING EXPENSES 2770 1579 360 831 2675 1525 348 802 13556516 9918693 2212232 1425591 1908312 2107359 1873971 1049345 669631 1212071 112347 69269 313290 233290 2375 80000 34459485 33033627 177236 518932 39203357 38070603 247245 361274 14388180 14132020 84868 421488 14720293 14914782 X 12729445 10207440 11753619 12948381 24483064 23155821 39203357 38070603 X -3508518 2002259 179016 X X 0 1 X 1 0 X 6224819 11263534 15386443 11556311 8538194 52969301 6224819 11263534 15386443 11556311 8538194 52969301 9979276 42990025 611749 542131 710226 1095100 992906 3952112 56921413 1777671 0.75530 0.71710 X 0.60030 0.06190 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 7500 14895 22395 12014365 12036760 751838 187960 0 0 704647 723133 837638 751838 3017256 4525884 22395 22395 176162 180783 209410 187960 754315 1131473 7500 7500 115471 115471 0 197819 117819 80000 80000 LEASE LIABILITY 421488 421488 X 12468752 2002259 512660 2514919 9953833 94165 94165 10047998 13795995 512660 512660 13283335 94165 179016 273181 13556516 PART X, LINE 2: OCRA RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. MANAGEMENT HAS DETERMINED THAT OCRA HAD NO UNCERTAIN TAX POSITIONS THAT WOULD REQUIRE FINANCIAL STATEMENT RECOGNITION OR DISCLOSURE. OCRA IS NO LONGER SUBJECT TO EXAMINATIONS BY THE APPLICABLE TAXING JURISDICTIONS FOR YEARS PRIOR TO DECEMBER 31, 2021. PART XII, LINE 4B - OTHER ADJUSTMENTS: GRANT REFUNDS 179,016. 1 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTMAKING 720000 NORTH AMERICA 0 0 GRANTMAKING 35000 0 0 0 0 0 0 755000 0 755000 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH 720000 WIRE 0 NORTH AMERICA RESEARCH 35000 WIRE 0 2 0 0 0 0 0 0 0 PART I, LINE 2: OCRA MONITORS THE USE OF GRANT FUNDS BY REQUIRING ALL GRANTEES TO SUBMIT YEARLY FINANCIAL AND NARRATIVE PROGRESS REPORTS DETAILING THE USE OF FUNDS AND PROGRAM OUTCOMES. THESE REPORTS ARE REVIEWED BY OCRA TO CONFIRM COMPLIANCE WITH THE STATED CHARITABLE OBJECTIVES. PART I, LINE 3: THE ORGANIZATION USED THE ACCRUAL METHOD OF ACCOUNTING TO ACCOUNT FOR EXPENDITURES. OVARIAN CYCLE & FITNESS 195891 195891 11079 195891 195891 11079 11079 -11079 1 THE GEORGE WASHINGTON UNIVERSITY CO/ TAX DEPARTMENT 44983 KNOLL SQUARE 2023 ASHBURN VA 201474198 530196584 501(C)(3) 900000 0 RESEARCH UNIVERSITY OF MINNESOTA COURTHOUSE DEPT 106 213 MAIN AVE N BAGLEY MN 56621 416007513 STATE OF MN 900000 0 RESEARCH CHILDREN'S HOSPITAL CORPORATION (DBA BOSTON CHILDREN'S HOSPITAL) 300 LONGWOOD AVE BOSTON MA 02115 042774441 501(C)(3) 899439 0 RESEARCH NORTHWESTERN UNIVERSITY 2145 SHERIDAN ROAD ROOM L291 EVANSTON IL 602083102 362167817 501(C)(3) 550000 0 RESEARCH WASHINGTON UNIVERSITY IN ST LOUIS WU-ACCT SVCS 7425 FORSYTH BLVD SAINT LOUIS MO 631052151 430653611 501(C)(3) 549837 0 RESEARCH JOHNS HOPKINS UNIVERSITY SOM 733 NORTH BROADWAY SUITE 117 BALTIMORE MD 21205 520595110 501(C)(3) 450000 0 RESEARCH H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC 12902 MAGNOLIA DRIVE TAMPA FL 33612 592451713 501(C)(3) 449803 0 RESEARCH UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE CB1270 CHAPEL HILL NC 275991270 566001393 STATE OF NC 200000 0 RESEARCH THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON 7000 FANNIN ST STE 1006 HOUSTON TX 770305400 741761309 STATE OF TX 199999 0 RESEARCH THE UNIVERSITY OF NEW MEXICO 1700 LOMAS BLVD NE ALBUQUERQUE NM 871063807 856000642 STATE OF NM 199987 0 RESEARCH STANFORD UNIVERSITY 485 BROADWAY MAIL CODE 8838 REDWOOD CITY CA 94063 941156365 501(C)(3) 100000 0 RESEARCH UNIVERSITY OF ILLINOIS AT CHICAGO 506 S WRIGHT ST 209 HAB NO MC339 URBANA IL 61801 376000511 STATE OF IL 99999 0 RESEARCH THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER PO BOX 301429 HOUSTON TX 77230 746001118 STATE OF TX 99000 0 RESEARCH SOCIETY OF GYNECOLOGIC ONCOLOGY 230 W MONROE STREET SUITE 710 CHICAGO IL 606064703 611657046 501(C)(6) 75000 0 RESEARCH 13 1 PART I, LINE 2: OCRA MONITORS THE USE OF GRANT FUNDS BY REQUIRING ALL GRANTEES TO SUBMIT YEARLY FINANCIAL AND NARRATIVE PROGRESS REPORTS DETAILING THE USE OF FUNDS AND PROGRAM OUTCOMES. THESE REPORTS ARE REVIEWED BY OCRA TO CONFIRM COMPLIANCE WITH THE STATED CHARITABLE OBJECTIVES. X X X 0 0 0 0 0 0 0 0 0 AUDRA L MORAN PRESIDENT & CEO 324287 0 0 0 0 0 12971 0 20981 0 358239 0 0 0 JONATHAN ZEIDMAN CHIEF DEVELOPMENT OFFICER 189019 0 0 0 0 0 0 0 53359 0 242378 0 0 0 SARAH C DEFEO CHIEF PROGRAM OFFICER 166391 0 0 0 0 0 7808 0 59486 0 233685 0 0 0 TRACY MOORE VICE PRESIDENT, SUPPORT & EDUCATION 157837 0 0 0 0 0 6314 0 20828 0 184979 0 0 0 NICOLE WARGO VP - PHILANTHROPIC PARTNER 126274 0 0 0 0 0 5360 0 30824 0 162458 0 0 0 X 16 684681 SALES PRICE 0 0 1 0 PART I, COLUMN (B): THE ORGANIZATION IS REPORTING THE NUMBER OF CONTRIBUTORS IN PART I, COLUMN (B) OF SCHEDULE M. FORM 990, PART I, ITEM C DBA: OVARIAN CANCER RESEARCH ALLIANCE DBA: THE EDMEE FIRTH FUND FOR RESEARCH ON OVARIAN CANCER DBA: THE EDMEE FIRTH FUND FOR RESEARCH IN OVARIAN CANCER FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PROVIDED TO THE BOARD OF DIRECTORS, AUDIT COMMITTEE, TREASURER, AND THE CEO, AND IS REVIEWED WITH THE EXTERNAL CPA PRIOR TO ITS FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C OCRA'S CONFLICT OF INTEREST POLICY (THE "POLICY") APPLIES TO DIRECTORS, OFFICERS AND OTHER EMPLOYEES OR OTHER PERSONS IN A POSITION TO INFLUENCE POLICY OR EXPENDITURES ("KEY PERSONS") WHO ARE ANNUALLY PROVIDED A COPY OF THE POLICY. THE POLICY INCLUDES A REPORTING FORM FOR EXISTING OR POTENTIAL CONFLICTS, AND EACH KEY PERSON IS REQUIRED TO COMPLETE ANNUALLY THE REPORTING FORM. IN CONNECTION WITH ANY PROPOSED TRANSACTION OR ARRANGEMENT BETWEEN OCRA AND ANY SUCH KEY PERSON OR RELATED PERSONS OR ENTITIES THAT RAISES AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST, THE KEY PERSON MUST DISCLOSE THE EXISTENCE AND NATURE OF HIS OR HER RELATIONSHIP AND FINANCIAL INTEREST TO THE PRESIDENT OR THE CHAIR OR CO-CHAIR OF THE BOARD OF DIRECTORS OR THE CHAIR OF ANY AUTHORIZED COMMITTEE. THE POLICY PROVIDES FOR CONSIDERATION OF ANY SUCH TRANSACTION OR ARRANGEMENT BY BOARD OR COMMITTEE MEMBERS BY FOLLOWING CERTAIN MEETING, DISCUSSION, VOTING AND DOCUMENTATION PROCEDURES. OTHER THAN TO PROVIDE INFORMATION OR RESPOND TO QUESTIONS, THE KEY PERSON IS EXCLUDED FROM THE DISCUSSION AND THE DECISION OF WHETHER A CONFLICT OF INTEREST EXISTS. FORM 990, PART VI, SECTION B, LINE 15 OCRA HAS A COMPENSATION COMMITTEE WHICH MEETS ANNUALLY TO REVIEW THE COMPENSATION OF THE CEO. THE COMPENSATION COMMITTEE DETERMINES THE CEO'S COMPENSATION BY UTILIZING DATA FROM COMPARABLY-SIZED ORGANIZATIONS (OBTAINED FORM 990 FILINGS). THE COMPENSATION DECISION IS DOCUMENTED IN THE RECORDS OF THE ORGANIZATION. SALARY INCREASES FOR KEY EMPLOYEES ARE RECOMMENDED BY THE CEO TO THE COMPENSATION COMMITTEE AFTER AN ANNUAL EVALUATION IS COMPLETED. THE COMPENSATION DECISION IS DOCUMENTED IN THE RECORDS OF THE ORGANIZATION. FORM 990, PART VI, SECTION C, LINE 19 FINANCIAL STATEMENTS ARE AVAILABLE ON OCRA'S WEBSITE. ALL OTHER DOCUMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART XI, LINE 9: GRANT REFUNDS 179,016. OVARIAN CANCER NATIONAL ALLIANCE 1101 14TH STREET NW SUITE 850 WASHINGTON DC 20005 311581756 EDUCATION AND ADVOCACY DC 501(C)(3) LINE 10 THE OVARIAN CANCER RESEARCH FUND INC 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0